loading

Finanzdaten der Denali Therapeutics Inc-Aktie (DNLI)

Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums 2025-06-30 2025-03-31 2024-09-30 2024-06-30 2024-03-31
Periodenlänge 3 Monate 3 Monate 3 Monate 3 Monate 3 Monate
Revenues
-
- - - 14.54
Operating Expenses
7.29%
134.96
145.58 123.19 116.59 132.25
Operating Income/Loss
7.29%
-134.96
-145.58 -123.19 -116.59 -117.72
Income/Loss From Continuing Operations Before Tax
6.66%
-124.12
-132.97 -107.19 -99.03 -101.80
Income/Loss From Continuing Operations After Tax
6.66%
-124.12
-132.97 -107.19 -99.03 -101.80
Net Income/Loss
6.66%
-124.12
-132.97 -107.19 -99.03 -101.80
Preferred Stock Dividends And Other Adjustments
-
- - - -
Attributable To Noncontrolling Interest
-
- - - -
Basic Average Shares
0.13%
171.45
171.22 169.46 168.83 149.40
Diluted Average Shares
0.13%
171.45
171.22 169.46 168.83 149.40
Basic Earnings Per Share
7.69%
-0.72
-0.78 -0.63 -0.59 -0.68
Diluted Earnings Per Share
7.69%
-0.72
-0.78 -0.63 -0.59 -0.68
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic
-
- - - -
$86.64
price up icon 1.40%
$27.54
price up icon 0.58%
$25.98
price up icon 9.16%
$112.46
price up icon 8.66%
$145.10
price up icon 1.80%
biotechnology ONC
$341.80
price up icon 7.24%
Kapitalisierung:     |  Volumen (24h):